Dr. Joseph Tucker

Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric's total to nine issued U.S. patents, enhancing the intellectual property surrounding its...

Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing: Cash and cash equivalents of $4.27...

Recently, at the Benzinga Psychedelic Capital Conference, leading experts from the biotech and pharmaceutical industry gathered to discuss the remarkable potential of psychedelics in medicine. Among the attendees was Enveric Biosciences Inc (NASDAQ: ENVB) CEO Dr. Joseph Tucker, who shared some...

Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline into a separate public company that will also be listed on the NASDAQ, and will be called Acanna Therapeutics Inc. CEO Dr. Joseph Tucker said...

There were more than 30 different companies in the psychedelic space present at the inaugural Benzinga Psychedelics Capital Conference on Tuesday. But, Enveric is one of the only ones that offer investors exposure to both the psychedelic and cannabis space. Enveric Biosciences Inc (NASDAQ...